Pharming Group (NASDAQ:PHAR) Shares Up 7.9% - Time to Buy?

Key Points

• Pharming Group's stock price surged by 7.9% on Monday, reaching a high of $11.84 with a substantial increase in trading volume, marking a 127% rise compared to its average daily volume.
• The company reported a net revenue of $93.20 million in its latest quarterly earnings, surpassing the consensus estimate of $70.36 million, and achieved an earnings per share of $0.06.
• Institutional investor Silverberg Bernstein Capital Management LLC increased its stake in Pharming Group by 8.6%, indicating growing interest in the company.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report)'s stock price rose 7.9% during mid-day trading on Monday . The company traded as high as $11.84 and last traded at $11.83. Approximately 12,350 shares traded hands during mid-day trading, an increase of 127% from the average daily volume of 5,443 shares. The stock had previously closed at $10.96.

Pharming Group Stock Performance

The firm has a market capitalization of $848.90 million, a PE ratio of -92.73 and a beta of 0.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.07 and a current ratio of 2.79. The company's fifty day moving average price is $10.84 and its two-hundred day moving average price is $9.54.

Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.16. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The firm had revenue of $93.20 million for the quarter, compared to analyst estimates of $70.36 million. As a group, equities analysts expect that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,147 shares of the company's stock after acquiring an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.08% of Pharming Group worth $557,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.03% of the company's stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.